In placebo-controlled trials for type 2 diabetes mellitus, an injection site reaction (e.g., injection-site discomfort, erythema) was reported in 0.2% of patients receiving semaglutide
Its pivotal trial enrolled 816 participants and met its primary efficacy endpoint, supporting FDA approval in 2010 with documented visceral fat reductions of roughly 15-18% over 26 weeks
131 , e148372 (2021)
MULTI-BENEFIT: B-12 supplementation aids in preventing anemia, promoting healthy hair and hooves, influencing positive mood and behavior, and safeguarding bone density, especially in aging horses.
Its action is specific to adipocytes (fat cells) via beta-3 adrenergic receptors and does not affect anabolic pathways, protein synthesis signaling, or IGF-1 levels
Rare side effects include mild irritation at the injection site or allergic reactions